ZINZINO AB (PUBL): PRELIMINARY SALES REPORT FEBRUARY 2019

STRONG SALES GROWTH DURING FEBRUARY; ZINZINO BASED REVENUE INCREASED 21% AND THE TOTAL GROUP REVENUE WITH 18% COMPARED WITH THE PREVIOUS YEAR.

The revenue for Zinzino's sales markets increasing by 21% to SEK 50.1 (41.4) million. Higher share of internal production during the month meant that Faun Pharma's external sales decreased by 22% and amounted to SEK 2.9 (3.7) million. Overall, the Group increased revenues by 18% to SEK 53.0 (45.1) million compared with the previous year.

Accumulated revenues for January-February increased with 16% to 106,5 (91,9) MSEK compared with the previous year.

Revenues distributed as follows:

Regions, MSEK Febr-19 Febr-18 Change 2019 2018 Change
Nordic Countries 29.8 31.2 -4% 60.7 61.7 -2%
Baltic States 4.7 3.6 29% 9.0 7.3 23%
Rest of Europa 13.6 5.1 168% 26.6 9.4 182%
North America 2.0 1.5 29% 3.7 3.2 16%
Zinzino 50.1 41.4 21% 100.0 81.6 23%
Faun Pharma 2.9 3.7 -22% 6.5 10.3 -37%
Zinzino Group 53.0 45.1 18% 106,5 91.9 16%

  
For more information please contact:
Dag Bergheim Pettersen, CEO Zinzino, tel. +47 (0) 932 25 700 www.zinzino.se

Pictures for free publication:
Marcus Tollbom, tel. +46 (0) 70-190 03 12

Certified Adviser:
Erik Penser Bank Aktiebolag: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se

Tags:

About Us

Zinzino AB (publ.) is a direct sales company which operates through the EU, North America and Australia. Zinzino markets and sells products in two product lines: Zinzino Health, with a focus on long-term health, and Zinzino Coffee, consisting of espresso machines, coffee and tea. Zinzino owns Norwegian BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino has over 120 employees. The company has its registered office in Gothenburg, and offices in Helsinki, Riga, Oslo, Florida and Brisbane. Zinzino is a public limited company and its shares are listed on Nasdaq First North.

Subscribe

Documents & Links